India Globalization Capital Competitors and Similar CompaniesClear all

India Globalization Capital's competitors and similar companies include Hemogenyx Pharmaceuticals, LifeMine Therapeutics, Sollis Therapeutics and Cour Pharmaceuticals Development.

	India Globalization Capital India Globalization Capital develops intellectual property for the treatment of life altering or life threatening conditions, through its research on phytocannabinoid-based therapies, in the United States.	Hemogenyx Pharmaceuticals Hemogenyx Pharmaceuticals, formerly Silver Falcon, is a pre-clinical stage biopharmaceutical company.	LifeMine Therapeutics LifeMine Therapeutics is a pharmaceutical company that develops fungi-based therapies.	Sollis Therapeutics Sollis Therapeutics is a pharmaceutical company developing non-steroid, non-opioid solutions to treat pain conditions.	Cour Pharmaceuticals Development Cour Pharmaceuticals Development is a company developing treatments and cures for immune-mediated diseases.
Founding Date	Founding Date 2005	Founding Date 2013	Founding Date 2017	Founding Date 2017	Founding Date 2012
Type	Type Public	Type Public	Type Private	Type Private	Type Private
Tags	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy	Tags Healthcare drug development pharma therapy
Locations	Locations Bethesda, US HQ	Locations London, GB HQ	Locations Cambridge, US HQ Basel, CH Gloucester, US	Locations Columbus, US HQ Hilliard, US	Locations Northbrook, US HQ
Employees	Employees 50150% increase	Employees 17	Employees 8215% decrease	Employees 29	Employees 761% increase
Valuation ($)	Valuation ($) 30 m	Valuation ($) 23.1 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $1.3m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $612k (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $733k (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ($13m) (FY, 2024)	Net income (£6.7m) (FY, 2023)	Net income N/A	Net income N/A	Net income N/A
Funding
Latest funding round	Latest funding round N/A	Latest funding round N/A	Latest funding round $ 55m (over 7 years ago)	Latest funding round $ 50m (about 7 years ago)	Latest funding round $ 17k (about 12 years ago)
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 55m	Total funding raised $ 50m	Total funding raised $ 17k